The three-year collaboration will also work for development of the Biospace Lab PhotonIMAGER Optima pre-clinical imaging platform.

The collaboration will bring together UCL experts in imaging and molecular probes, together with expertise from Biospace Lab to develop novel molecular imaging technologies for biomedical research applications.

It will initially focus on further method development in luminescence imaging and the integration of in vivo optical imaging with other in vivo imaging modalities, in addition to support a range of Biomedical research projects at UCL.

Biospace Lab CEO Olivier Merle said: "We are very excited by the opportunity to combine our expertise with that of CABI and we are convinced that this synergistic partnership will open up many new possibilities for developments in pre-clinical Molecular Imaging, thereby expanding the range of imaging solutions offered to the biomedical research community by our unique technologies."

The UCL Centre for Advanced Biomedical Imaging (CABI) director Mark Lythgoe said the partnership reflects the university’s desire to collaborate with companies that share its aims: the development and application of novel in vivo imaging technologies.

"I believe that the new PhotonIMAGER Optima system will prove to be essential in probing tissue structure and function in our experimental imaging armoury at UCL," Lythgoe said.